Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to -$690837.0.

  • Cumberland Pharmaceuticals' Cash from Investing Activities fell 46428.67% to -$690837.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 58074.6%. This contributed to the annual value of $57842.0 for FY2024, which is 15472.54% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$690837.0 for Q3 2025, which was down 46428.67% from $285864.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $680805.0 during Q3 2022, with a 5-year trough of -$13.5 million in Q1 2022.
  • Its 5-year average for Cash from Investing Activities is -$834597.9, with a median of -$95073.0 in 2023.
  • Over the last 5 years, Cumberland Pharmaceuticals' Cash from Investing Activities had its largest YoY gain of 72895.4% in 2022, and its largest YoY loss of 415389.69% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$26795.0 in 2021, then tumbled by 2291.39% to -$640772.0 in 2022, then surged by 140.68% to $260639.0 in 2023, then crashed by 110.29% to -$26809.0 in 2024, then tumbled by 2476.88% to -$690837.0 in 2025.
  • Its Cash from Investing Activities stands at -$690837.0 for Q3 2025, versus $285864.0 for Q2 2025 and -$1.2 million for Q1 2025.